» Articles » PMID: 27712766

Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease

Overview
Date 2016 Oct 8
PMID 27712766
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C synthase (LTCS), resulting in constitutive overproduction of cysteinyl leukotrienes. Mast cells and eosinophils have roles in mediating many of the observed effects. Increased levels of both interleukin-4 (IL-4) and interferon (IFN)-γ are present in the tissue of patients with AERD. Previous studies showed that IL-4 is primarily responsible for the upregulation of LTCS by mast cells. Our studies show that IFN-γ, but not IL-4, drives this process in eosinophils. This article examines the overall role that eosinophils and mast cells contribute to the pathophysiology of AERD.

Citing Articles

Low Prostaglandin E but High Prostaglandin D, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway Epithelium.

Picado C, Machado-Carvalho L, Roca-Ferrer J J Clin Med. 2024; 13(23).

PMID: 39685875 PMC: 11642301. DOI: 10.3390/jcm13237416.


Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.

Ley-Tomas J, Xicotencatl-Tellez A, Garcia-Cruz M, Jimenez-Chobillon M Front Allergy. 2024; 5:1462985.

PMID: 39665076 PMC: 11631927. DOI: 10.3389/falgy.2024.1462985.


Using machine learning for the personalised prediction of revision endoscopic sinus surgery.

Nuutinen M, Haukka J, Virkkula P, Torkki P, Toppila-Salmi S PLoS One. 2022; 17(4):e0267146.

PMID: 35486626 PMC: 9053825. DOI: 10.1371/journal.pone.0267146.


Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Rhyou H, Nam Y, Park H Allergy Asthma Immunol Res. 2022; 14(2):153-167.

PMID: 35255534 PMC: 8914608. DOI: 10.4168/aair.2022.14.2.153.


Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Mullol J, Laidlaw T, Bachert C, Mannent L, Canonica G, Han J Allergy. 2021; 77(4):1231-1244.

PMID: 34459002 PMC: 9292324. DOI: 10.1111/all.15067.


References
1.
Hamilos D, Leung D, Huston D, Kamil A, Wood R, Hamid Q . GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy. 1998; 28(9):1145-52. DOI: 10.1046/j.1365-2222.1998.00380.x. View

2.
Park H, Nahm D, Park K, Suh K, Yim H . Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol. 1998; 81(3):219-24. DOI: 10.1016/s1081-1206(10)62815-3. View

3.
Steinke J, Liu L, Huyett P, Negri J, Payne S, Borish L . Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2013; 132(4):856-65.e1-3. PMC: 3788084. DOI: 10.1016/j.jaci.2013.05.008. View

4.
Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M . Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998; 157(4 Pt 1):1187-94. DOI: 10.1164/ajrccm.157.4.9707089. View

5.
Nerlov C, Graf T . PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998; 12(15):2403-12. PMC: 317050. DOI: 10.1101/gad.12.15.2403. View